Comparative Study Of Hepatocellular Carcinoma Treated By Transcatheter Arteria Chemoembolization With Different Size Of Microspheres

Objects To compare the short-term clinical efficacy and safety of unresectable hepatocellular carcinoma(HCC)treated by Transcatheter Arterial Chemoembolization(TACE)with two different sizes of Embosphere(Embosphere40-120 u m and Embosphere 100-300 μm).Materials and methods 64 patients with imaging proven HCC treated with C-TACE combined with Embosphere were divided into two groups:the experimental group(n=32,C-TACE + Embosphere 40-120 μm)and the control group(n=32,C-TACE + Embosphere 40-120 μm).after therapy for 4-6 weeks,all patients had adequate radiographic imaging with either CT or MRI,used the mRESIST standard to evaluate The short-term imaging response,objective response rate,clinical benefit rate;serum alpha-fetoprotein(AFP)changes,patients ’ liver and kidney function changes,procedure-related complications were analyzed respectively before and after therapy.Results Enhanced CT or MRI 4-6 weeks after therapy,in the experimental group,complete response(CR)was 11 cases,partial response(PR)was 14 cases,stable disease(SD)was 5 cases,and progressive disease(PD)was 2 cases,the objective response rate(CR+PR)was 78.1%and clinical benefit rate(CR+PR+SD)was 93.8%.In the control group,CR was 6 cases,PR was 10 cases,SD was 7 cases,and PD was 9 cases,the objective response rate was(CR+PR)50.0%and clinical benefit rate(CR+PR+SD)was 71.9%,the difference of the objective response rate and clinical benefit rate was statistically significant(P<0.05),moreover,the AFP change was in a statistically significant difference(P<0.05)after treatment.There was no significant difference in liver and kidney function before and after therapy between the two groups(P>0.05).There was no significant difference in adverse reaction between the two groups(P>0.05).Conclusion It’s safe to treating HCC with the C-TACE combine with Embosphere(40-120 μm)and Embosphere(100-300 μm)microspheres,In short-term,Patients with HCC can benefit from the Embosphere(40-120μm)microspheres combined with C-TACE,especially in the objective response rate and clinical benefit rate.